FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer

Abstract Background The OPUS study demonstrated that addition of cetuximab to 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX4) significantly improved objective response and progression-free survival (PFS) in the first-line treatment of patients with KRAS exon 2 wild-type metastatic colorectal...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2015-07, Vol.51 (10), p.1243-1252
Hauptverfasser:	Bokemeyer, C, Köhne, C.-H, Ciardiello, F, Lenz, H.-J, Heinemann, V, Klinkhardt, U, Beier, F, Duecker, K, van Krieken, J.H, Tejpar, S
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cetuximab Codon Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Disease-Free Survival Exons Fluorouracil - administration & dosage FOLFOX4 Genes, ras Hematology, Oncology and Palliative Medicine Humans KRAS Leucovorin - administration & dosage Mutation NRAS OPUS Organoplatinum Compounds - administration & dosage RAS
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!